GPM Reminds Investors of the November 21st Deadline in the Class Action Lawsuit Against Spectrum Pharmaceuticals, Inc. & Enco...
October 31 2016 - 3:51PM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the
November 21, 2016 deadline to file a lead plaintiff motion
in the class action lawsuit filed on behalf of investors who
purchased or otherwise acquired Spectrum Pharmaceuticals, Inc.
(“Spectrum” or the “Company”) (NASDAQ: SPPI) securities between
February 28, 2013 and September 16, 2016, inclusive (the
“Class Period”). Spectrum investors have until November 21,
2016 to file a lead plaintiff motion.
The class action complaint filed on behalf of shareholders
alleges that throughout the Class Period defendants made false
and/or misleading statements and/or failed to disclose that: (1)
the FDA previously questioned whether the data from the 611 and 612
Studies were clinically meaningful; (2) the FDA advised defendants
in December 2012 not to submit the New Drug Application based on
data from the 611 and 612 Studies; and (3) as a result, defendants'
public statements about Spectrum's business, operations and
prospects were materially false and misleading at all relevant
times. When the true details entered the market, the lawsuit claims
that investors suffered damages.
If you purchased or otherwise acquired Spectrum shares during
the Class Period, you may move the Court no later
than November 21, 2016 to request appointment as
lead plaintiff. To be a member of the class you need not take any
action at this time; you may retain counsel of your choice or take
no action and remain an absent member of the Class. If you wish
to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests
with respect to these matters, please contact Lesley Portnoy,
Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by
email to shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161031006226/en/
Glancy Prongay & Murray LLP, Los AngelesLesley Portnoy,
310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2024 to May 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From May 2023 to May 2024